Payment overview · 2025
General Payments
$37.46
2 reported records · 2 companies
Healthcare provider profile · identity verified
Shirley Nelson, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · NANUET, NY · NPI 1871654897
Verified facts
What the public records show
CMS Open Payments records show Shirley Nelson, D.O. received $37.46 in general payments during 2025 across 2 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 59.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.43 | 59.9% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.03 | 40.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.46 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 75 |
| Metformin Hcl | Metformin Hcl | 241 | 48 |
| Famotidine | Famotidine | 197 | 32 |
| Divalproex Sodium | Divalproex Sodium | 152 | 17 |
| Omeprazole | Omeprazole | 150 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 24 |
| Losartan Potassium | Losartan Potassium | 113 | 27 |
| Mirtazapine | Mirtazapine | 111 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 108 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 27 |
| Memantine Hcl | Memantine Hcl | 95 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 95 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 20 |
| Risperidone | Risperidone | 81 | 11 |
| Amantadine | Amantadine Hcl | 80 | suppressed |
| Gabapentin | Gabapentin | 78 | 20 |
| Levetiracetam | Levetiracetam | 74 | 11 |
| Eliquis | Apixaban | 73 | 15 |
| Finasteride | Finasteride | 73 | suppressed |
| Baclofen | Baclofen | 72 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 72 | 13 |
| Simvastatin | Simvastatin | 72 | 16 |
| Lisinopril | Lisinopril | 70 | 23 |
| Clozapine | Clozapine | 68 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 15 |
| Furosemide | Furosemide | 63 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 17 |
| Donepezil Hcl | Donepezil Hcl | 62 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 60 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 57 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 11 |
| Alprazolam | Alprazolam | 51 | 13 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Allopurinol | Allopurinol | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Lactulose | Lactulose | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | 18 |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | 13 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 23 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Carvedilol | Carvedilol | 22 | 12 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Digoxin | Digoxin | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Exemestane | Exemestane | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.46 · 2 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | DAYBUE, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Salix Pharmaceuticals, a division of Bausch Health US, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error